What you need to know about the shift from manufacturer-based oversight to the new risk-based approach for LDTs.
Since 2014, the FDA has been adopting a risk-based approach to regulatory oversight for LDTs which replaced the older system which focused on the type of manufacturer or laboratory involved.
In this Webinar, instructor Larry Stevens, RAC, will walk you through this new risk-based approach in detail, giving you all the information you need to anticipate the new regulations.
You’ll learn:
68 Harrison Ave Ste 605
PMB 490101
Boston, Massachusetts 02111
(508) 926-8330
info@thefdagroup.comProprietary talent selection of former FDA and industry professionals amplified by a corporate culture of responsiveness and execution.
68 Harrison Ave Ste 605
PMB 490101
Boston, Massachusetts 02111
US Toll-Free: 1-833-FDA-GROUP
International: +001 508 926 8330
The FDA Group will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information. Privacy Policy.